4147 fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
TaiMed Biologics, Inc. engages in the new drug development for human immunodeficiency virus (HIV). Its products include: (1) TMB-355 for the latter part of acquired immune deficiency syndrome (AIDS) medication. (2) TMB-360/365 for anti-AIDS virus. (3) TMB-607 Protease inhibitors for the anti-AIDS virus. The company was founded by David Ho, LanBo Chen and Ing-Wen Tsai on September 4, 2007 and is headquartered in Taipei, Taiwan.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
4147 has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company